CMRX - Rasio cepet Chimerix, Inc.

Chimerix, Inc. (CMRX) possesses significant market influence due to Tembexa, an indispensable treatment for smallpox. This daily price action on GURU.Markets reflects the asset's dynamics, where the coefficient is 5.66. The business generates revenue through government contracts and oncology partnerships. Investors are awaiting the results of Phase 3 trials for ONC201 in glioma, while current R&D expenditures are already priced in.

For the Chimerix, Inc. (CMRX) biotech ecosystem, the current acid-test ratio reflects the company's ability to meet short-term obligations without liquidating inventory. This metric assesses the proportion of the most liquid assets, excluding hard-to-sell pharmaceuticals from the solvency calculation. The formula compares the sum of cash and accounts receivable against the volume of current liabilities. For this vendor of unique oncology protocols, this indicator serves as the primary safeguard against cash flow gaps.